Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a
nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults
has already been established. It is reported that tipepidine inhibits G-protein-coupled
inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by
tipepidine is expected to modulate the level of monoamines in the brain. We put forward the
hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD)
symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK
channels. The purpose of this double-blind, placebo-controlled trial is to confirm whether
treatment with tipepidine can improve symptoms in pediatric patients with ADHD.